{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:42:31Z","timestamp":1784720551869,"version":"3.55.0"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"14","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Among the proinflammatory mediators, platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine) is a major primary and secondary messenger involved in intracellular and extracellular communication. Evidence suggests that PAF plays a significant role in oncogenic transformation, tumor growth, angiogenesis, and metastasis. However, PAF, with its receptor (PAFR) and their downstream signaling targets, has not been thoroughly studied in cancer. Here, we characterized the PAFR expression pattern in 4 normal human ovarian surface epithelial (HOSE) cell lines, 13 ovarian cancer cell lines, paraffin blocks (n = 84), and tissue microarrays (n = 230) from patients with ovarian cancer. Overexpression of PAFR was found in most nonmucinous types of ovarian cancer but not in HOSE and mucinous cancer cells. Correspondingly, PAF significantly induced cell proliferation and invasion only in PAFR-positive cells (i.e., OVCA429 and OVCA432), but not in PAFR-negative ovarian cells (HOSE and mucinous RMUG-L). The dependency of cell proliferation and invasion on PAFR was further confirmed using PAFR-specific small interfering RNA gene silencing probes, antibodies against PAFR and PAFR antagonist, ginkgolide B. Using quantitative multiplex phospho-antibody array technology, we found that tyrosine phosphorylation of EGFR\/Src\/FAK\/paxilin was coordinately activated by PAF treatment, which was correlated with the activation of phosphatidylinositol 3-kinase and cyclin D1 as markers for cell proliferation, as well as matrix metalloproteinase 2 and 9 for invasion. Specific tyrosine Src inhibitor (PP2) reversibly blocked PAF-activated cancer cell proliferation and invasion. We suggest that PAFR is an essential upstream target of Src and other signal pathways to control the PAF-mediated cancer progression. [Cancer Res 2008;68(14):5839\u201348]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-5771","type":"journal-article","created":{"date-parts":[[2008,7,16]],"date-time":"2008-07-16T04:19:59Z","timestamp":1216181999000},"page":"5839-5848","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Activation of Platelet-Activating Factor Receptor and Pleiotropic Effects on Tyrosine Phospho-EGFR\/Src\/FAK\/Paxillin in Ovarian Cancer"],"prefix":"10.1158","volume":"68","author":[{"given":"Margarita","family":"Aponte","sequence":"first","affiliation":[{"name":"1Laboratory of Gynecologic Oncology and Epidemiology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Center, Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Laboratory of Gynecologic Oncology and Epidemiology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Center, Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montaha","family":"Lakkis","sequence":"additional","affiliation":[{"name":"2BioSource, Invitrogen, Inc., Carlsbad, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jiang","family":"Li","sequence":"additional","affiliation":[{"name":"1Laboratory of Gynecologic Oncology and Epidemiology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Center, Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Edwards","sequence":"additional","affiliation":[{"name":"1Laboratory of Gynecologic Oncology and Epidemiology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Center, Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Albitar","sequence":"additional","affiliation":[{"name":"1Laboratory of Gynecologic Oncology and Epidemiology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Center, Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Vitonis","sequence":"additional","affiliation":[{"name":"1Laboratory of Gynecologic Oncology and Epidemiology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Center, Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel C.","family":"Mok","sequence":"additional","affiliation":[{"name":"1Laboratory of Gynecologic Oncology and Epidemiology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Center, Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Cramer","sequence":"additional","affiliation":[{"name":"1Laboratory of Gynecologic Oncology and Epidemiology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Center, Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Ye","sequence":"additional","affiliation":[{"name":"1Laboratory of Gynecologic Oncology and Epidemiology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Dana-Farber Cancer Center, Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,7,15]]},"reference":[{"key":"2022061700272168900_B1","doi-asserted-by":"crossref","unstructured":"Zhu T, Gobeil F, Vazquez-Tello A, et al. Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE2, PAF, LPA1 receptors. Can J Physiol Pharmacol\u20082006; 84: 377\u201391.","DOI":"10.1139\/y05-147"},{"key":"2022061700272168900_B2","doi-asserted-by":"crossref","unstructured":"Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci\u20082003; 40: 643\u201372.","DOI":"10.1080\/714037693"},{"key":"2022061700272168900_B3","doi-asserted-by":"crossref","unstructured":"Boccellino M, Camussi G, Giovane A, et al. Platelet-activating factor regulates cadherin-catenin adhesion system expression and \u03b2-catenin phosphorylation during Kaposi's sarcoma cell motility. Am J Pathol\u20082005; 166: 1515\u201322.","DOI":"10.1016\/S0002-9440(10)62367-X"},{"key":"2022061700272168900_B4","doi-asserted-by":"crossref","unstructured":"Hikiji H, Ishii S, Shindou H, Takato T, Shimizu T. Absence of platelet-activating factor receptor protects mice from osteoporosis following ovariectomy. J Clin Invest\u20082004; 114: 85\u201393.","DOI":"10.1172\/JCI20504"},{"key":"2022061700272168900_B5","doi-asserted-by":"crossref","unstructured":"Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu Rev Biochem\u20082000; 69: 419\u201345.","DOI":"10.1146\/annurev.biochem.69.1.419"},{"key":"2022061700272168900_B6","doi-asserted-by":"crossref","unstructured":"Eisinger AL, Prescott SM, Jones DA, Stafforini DM. The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat\u20082007; 82: 147\u201354.","DOI":"10.1016\/j.prostaglandins.2006.05.026"},{"key":"2022061700272168900_B7","doi-asserted-by":"crossref","unstructured":"Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem\u20082001; 276: 18075\u201381.","DOI":"10.1074\/jbc.M009689200"},{"key":"2022061700272168900_B8","doi-asserted-by":"crossref","unstructured":"Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell\u20081995; 83: 493\u2013501.","DOI":"10.1016\/0092-8674(95)90127-2"},{"key":"2022061700272168900_B9","doi-asserted-by":"crossref","unstructured":"Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer\u20082003; 3: 582\u201391.","DOI":"10.1038\/nrc1143"},{"key":"2022061700272168900_B10","doi-asserted-by":"crossref","unstructured":"Symowicz J, Adley BP, Woo MM, et al. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res\u20082005; 65: 2234\u201342.","DOI":"10.1158\/0008.5472.CAN-04-2781"},{"key":"2022061700272168900_B11","doi-asserted-by":"crossref","unstructured":"Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer\u20082006; 6: 130\u201340.","DOI":"10.1038\/nrc1801"},{"key":"2022061700272168900_B12","doi-asserted-by":"crossref","unstructured":"Boucharaba A, Serre CM, Gres S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest\u20082004; 114: 1714\u201325.","DOI":"10.1172\/JCI200422123"},{"key":"2022061700272168900_B13","doi-asserted-by":"crossref","unstructured":"Walterscheid JP, Ullrich SE, Nghiem DX. Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J Exp Med\u20082002; 195: 171\u20139.","DOI":"10.1084\/jem.20011450"},{"key":"2022061700272168900_B14","doi-asserted-by":"crossref","unstructured":"Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer\u20082007; 7: 139\u201347.","DOI":"10.1038\/nrc2067"},{"key":"2022061700272168900_B15","doi-asserted-by":"crossref","unstructured":"Liebmann C. G protein-coupled receptors and their signaling pathways: classical therapeutical targets susceptible to novel therapeutic concepts. Curr Pharm Des\u20082004; 10: 1937\u201358.","DOI":"10.2174\/1381612043384367"},{"key":"2022061700272168900_B16","doi-asserted-by":"crossref","unstructured":"Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer\u20082007; 7: 79\u201394.","DOI":"10.1038\/nrc2069"},{"key":"2022061700272168900_B17","doi-asserted-by":"crossref","unstructured":"Kume K, Shimizu T. Platelet-activating factor (PAF) induces growth stimulation, inhibition, and suppression of oncogenic transformation in NRK cells overexpressing the PAF receptor. J Biol Chem\u20081997; 272: 22898\u2013904.","DOI":"10.1074\/jbc.272.36.22898"},{"key":"2022061700272168900_B18","doi-asserted-by":"crossref","unstructured":"Heon Seo K, Ko HM, Kim HA, et al. Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-\u03baB activation. Cancer Res\u20082006; 66: 4681\u20136.","DOI":"10.1158\/0008-5472.CAN-05-3186"},{"key":"2022061700272168900_B19","doi-asserted-by":"crossref","unstructured":"Melnikova VO, Mourad-Zeidan AA, Lev DC, Bar-Eli M. Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem\u20082006; 281: 2911\u201322.","DOI":"10.1074\/jbc.M508683200"},{"key":"2022061700272168900_B20","doi-asserted-by":"crossref","unstructured":"Denizot Y, Descottes B, Truffinet V, et al. Platelet-activating factor and liver metastasis of colorectal cancer. Int J Cancer\u20082005; 113: 503\u20135.","DOI":"10.1002\/ijc.20585"},{"key":"2022061700272168900_B21","doi-asserted-by":"crossref","unstructured":"Ishii S, Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res\u20082000; 39: 41\u201382.","DOI":"10.1016\/S0163-7827(99)00016-8"},{"key":"2022061700272168900_B22","doi-asserted-by":"crossref","unstructured":"Lukashova V, Asselin C, Krolewski JJ, Rola-Pleszczynski M, Stankova J. G-protein-independent activation of Tyk2 by the platelet-activating factor receptor. J Biol Chem\u20082001; 276: 24113\u201321.","DOI":"10.1074\/jbc.M100720200"},{"key":"2022061700272168900_B23","doi-asserted-by":"crossref","unstructured":"Deo DD, Axelrad TW, Robert EG, et al. Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J Biol Chem\u20082002; 277: 21237\u201345.","DOI":"10.1074\/jbc.M110955200"},{"key":"2022061700272168900_B24","unstructured":"Soldi R, Sanavio F, Aglietta M, et al. Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125FAK) in human endothelial cells. Oncogene\u20081996; 13: 515\u201325."},{"key":"2022061700272168900_B25","doi-asserted-by":"crossref","unstructured":"Marques SA, Dy LC, Southall MD, et al. The platelet-activating factor receptor activates the extracellular signal-regulated kinase mitogen-activated protein kinase and induces proliferation of epidermal cells through an epidermal growth factor-receptor-dependent pathway. J Pharmacol Exp Ther\u20082002; 300: 1026\u201335.","DOI":"10.1124\/jpet.300.3.1026"},{"key":"2022061700272168900_B26","doi-asserted-by":"crossref","unstructured":"Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta\u20082002; 1582: 257\u201364.","DOI":"10.1016\/S1388-1981(02)00179-8"},{"key":"2022061700272168900_B27","doi-asserted-by":"crossref","unstructured":"Gupta GP, Massague J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest\u20082004; 114: 1691\u20133.","DOI":"10.1172\/JCI200423823"},{"key":"2022061700272168900_B28","doi-asserted-by":"crossref","unstructured":"Ye B, Aponte M, Dai Y, et al. Ginkgo biloba and ovarian cancer prevention: Epidemiological and biological evidence. Cancer Lett\u20082007; 251: 43\u201352.","DOI":"10.1016\/j.canlet.2006.10.025"},{"key":"2022061700272168900_B29","doi-asserted-by":"crossref","unstructured":"Tsao SW, Mok SC, Fey EG, et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res\u20081995; 218: 499\u2013507.","DOI":"10.1006\/excr.1995.1184"},{"key":"2022061700272168900_B30","doi-asserted-by":"crossref","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods\u20081983; 65: 55\u201363.","DOI":"10.1016\/0022-1759(83)90303-4"},{"key":"2022061700272168900_B31","doi-asserted-by":"crossref","unstructured":"Tsuda H, Ito YM, Ohashi Y, et al. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res\u20082005; 11: 6880\u20138.","DOI":"10.1158\/1078-0432.CCR-05-0751"},{"key":"2022061700272168900_B32","doi-asserted-by":"crossref","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-\u0394\u0394C(T)) method. Methods\u20082001; 25: 402\u20138.","DOI":"10.1006\/meth.2001.1262"},{"key":"2022061700272168900_B33","doi-asserted-by":"crossref","unstructured":"Garcia Rodriguez C, Cundell DR, Tuomanen EI, et al. The role of N-glycosylation for functional expression of the human platelet-activating factor receptor. Glycosylation is required for efficient membrane trafficking. J Biol Chem\u20081995; 270: 25178\u201384.","DOI":"10.1074\/jbc.270.42.25178"},{"key":"2022061700272168900_B34","doi-asserted-by":"crossref","unstructured":"Melnikova V, Bar-Eli M. Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer Metastasis Rev\u20082007; 26: 359\u201371.","DOI":"10.1007\/s10555-007-9092-9"},{"key":"2022061700272168900_B35","unstructured":"Im SY, Ko HM, Kim JW, et al. Augmentation of tumor metastasis by platelet-activating factor. Cancer Res\u20081996; 56: 2662\u20135."},{"key":"2022061700272168900_B36","unstructured":"Biancone L, Cantaluppi V, Del Sorbo L, et al. Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth. Clin Cancer Res\u20082003; 9: 4214\u201320."},{"key":"2022061700272168900_B37","doi-asserted-by":"crossref","unstructured":"Mutoh H, Ishii S, Izumi T, Kato S, Shimizu T. Platelet-activating factor (PAF) positively auto-regulates the expression of human PAF receptor transcript 1 (leukocyte-type) through NF-\u03baB. Biochem Biophys Res Commun\u20081994; 205: 1137\u201342.","DOI":"10.1006\/bbrc.1994.2784"},{"key":"2022061700272168900_B38","doi-asserted-by":"crossref","unstructured":"Dagenais P, Thivierge M, Parent JL, Stankova J, Rola-Pleszczynski M. Augmented expression of platelet-activating factor receptor gene by TNF-\u03b1 through transcriptional activation in human monocytes. J Leukoc Biol\u20081997; 61: 106\u201312.","DOI":"10.1002\/jlb.61.1.106"},{"key":"2022061700272168900_B39","doi-asserted-by":"crossref","unstructured":"Bussolati B, Biancone L, Cassoni P, et al. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol\u20082000; 157: 1713\u201325.","DOI":"10.1016\/S0002-9440(10)64808-0"},{"key":"2022061700272168900_B40","doi-asserted-by":"crossref","unstructured":"Cellai C, Laurenzana A, Vannucchi AM, et al. Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086. Br J Cancer\u20082006; 94: 1637\u201342.","DOI":"10.1038\/sj.bjc.6603156"},{"key":"2022061700272168900_B41","doi-asserted-by":"crossref","unstructured":"Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol\u20082007; 213: 589\u2013602.","DOI":"10.1002\/jcp.21246"},{"key":"2022061700272168900_B42","doi-asserted-by":"crossref","unstructured":"Mollapour E, Linch DC Roberts PJ. Activation and priming of neutrophil nicotinamide adenine dinucleotide phosphate oxidase and phospholipase A(2) are dissociated by inhibitors of the kinases p42(ERK2) and p38(SAPK) and by methyl arachidonyl fluorophosphonate, the dual inhibitor of cytosolic and calcium-independent phospholipase A(2). Blood\u20082001; 97: 2469\u201377.","DOI":"10.1182\/blood.V97.8.2469"},{"key":"2022061700272168900_B43","doi-asserted-by":"crossref","unstructured":"Sotsios Y, Ward SG. Phosphoinositide 3-kinase: a key biochemical signal for cell migration in response to chemokines. Immunol Rev\u20082000; 177: 217\u201335.","DOI":"10.1034\/j.1600-065X.2000.17712.x"},{"key":"2022061700272168900_B44","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T. Transforming growth factor-\u03b21-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. J Biol Chem\u20082004; 279: 8567\u201376.","DOI":"10.1074\/jbc.M309131200"},{"key":"2022061700272168900_B45","doi-asserted-by":"crossref","unstructured":"McLean GW, Carragher NO, Avizienyte E, et al. The role of focal-adhesion kinase in cancer\u2014a new therapeutic opportunity. Nat Rev Cancer\u20082005; 5: 505\u201315.","DOI":"10.1038\/nrc1647"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/14\/5839\/2598070\/5839.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/14\/5839\/2598070\/5839.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T04:51:18Z","timestamp":1655441478000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/14\/5839\/541715\/Activation-of-Platelet-Activating-Factor-Receptor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,15]]},"references-count":45,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2008,7,15]]},"published-print":{"date-parts":[[2008,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-5771","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,15]]}}}